Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 12:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Leptin administration Clear all
Terminated Phase 2 Interventional Results available

A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

NCT05088460
View directory record Official record
Conditions
Familial Partial Lipodystrophy, Metabolic Abnormalities
Interventions
REGN4461, Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Boca Raton, Florida • Bethesda, Maryland • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 23, 2026, 12:24 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance

NCT00085982
View directory record Official record
Conditions
Severe Insulin Resistance
Interventions
Metreleptin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
5 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 23, 2026, 12:24 PM EDT
Completed Not applicable Interventional

Biomarkers in Obstructive Sleep Apnea Surgery

NCT00507078
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Surgical treatment for OSA
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 23, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome

NCT00362440
View directory record Official record
Conditions
HIV Lipodystrophy
Interventions
Leptin, Pioglitazone or metformin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 23, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

NCT04963231
View directory record Official record
Conditions
Genetic Obesity
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Scottsdale, Arizona • Suwanee, Georgia • Worcester, Massachusetts + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 23, 2026, 12:24 PM EDT
Completed Not applicable Interventional

Measuring Effectiveness in Sleep Apnea Surgery

NCT00518128
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Surgical OSA treatment, Positive Airway Pressure Therapy
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Sep 23, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity

NCT03013543
View directory record Official record
Conditions
Genetic Obesity, Obesity, Obesity Due to Melanocortin 4 Receptor Deficiency
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
43
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Sep 23, 2026, 12:24 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)

NCT00787644
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Sep 23, 2026, 12:24 PM EDT
Completed Phase 3 Interventional

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

NCT06548100
View directory record Official record
Conditions
Generalized Lipodystrophy
Interventions
mibavademab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 23, 2026, 12:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Novel Screening Tools For the Evaluation and Management of Malnourished Children in the Developing World

NCT02449408
View directory record Official record
Conditions
Overweight, Obesity, Small for Gestational Age, Prematurity
Interventions
Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool
Other
Lead sponsor
Duke University
Other
Eligibility
1 Hour to 18 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 23, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Therapeutic Approaches to HAART-Induced Lipodystrophy

NCT00461552
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Leptin, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
14 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 23, 2026, 12:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

To Determine if Sleep Deprivation Results in Increased Esophageal Acid Exposure

NCT01093339
View directory record Official record
Conditions
Gastroesophageal Disease
Interventions
Not listed
Lead sponsor
Southern Arizona VA Health Care System
Federal
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Sep 23, 2026, 12:24 PM EDT
Completed No phase listed Observational

Pharmacodynamics of CNP During Growth Hormone Treatment

NCT01504802
View directory record Official record
Conditions
Pituitary Dwarfism, Idiopathic Short Stature
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Sep 23, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Leptin to Treat Lipodystrophy

NCT00025883
View directory record Official record
Conditions
Lipodystrophy
Interventions
Metreleptin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Sep 23, 2026, 12:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Leptin Administration After Roux-en-Y Gastric Bypass

NCT00710814
View directory record Official record
Conditions
Overweight
Interventions
Leptin, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2015 · Synced Sep 23, 2026, 12:24 PM EDT
Completed Phase 4 Interventional Results available

A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa

NCT00140426
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Risperidone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Sep 23, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

In Vivo Leptin Signaling in Humans After Acute Leptin Administration

NCT01275053
View directory record Official record
Conditions
Lean, Obese, Obese Diabetics
Interventions
leptin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 23, 2026, 12:24 PM EDT
Completed Phase 2 Interventional

Leptin to Treat Lipodystrophy

NCT00005905
View directory record Official record
Conditions
Lipodystrophy
Interventions
hu Leptin (A-100)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 23, 2026, 12:24 PM EDT
Completed Phase 2 Interventional

Setmelanotide in a Single Patient With Partial Lipodystrophy

NCT03262610
View directory record Official record
Conditions
Hypertriglyceridemia, Obesity
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
15 Years to 15 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Sep 23, 2026, 12:24 PM EDT
Active, not recruiting Phase 3 Interventional

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

NCT02262832
View directory record Official record
Conditions
Lipodystrophy, Diabetes, Hyperlipidemia
Interventions
Metreleptin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 98 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 12:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Secondary Analysis of Gut Hormones and Inflammatory Cytokines in Fasting Subjects

NCT01257841
View directory record Official record
Conditions
Healthy
Interventions
Leptin administration, Fasting
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2010 · Synced Sep 23, 2026, 12:24 PM EDT